Dowling & Yahnke’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $10.5M | Sell |
78,132
-545
| -0.7% | -$78.2K | 0.49% | 43 |
|
|
2022
Q2 | $12.1M | Sell |
78,677
-195
| -0.2% | -$29.8K | 0.57% | 38 |
|
|
2022
Q1 | $12.8M | Sell |
78,872
-576
| -0.7% | -$83.7K | 0.56% | 42 |
|
|
2021
Q4 | $10.8M | Sell |
79,448
-501
| -0.6% | -$59.2K | 0.52% | 57 |
|
|
2021
Q3 | $8.62M | Buy |
79,949
+823
| +1% | +$94K | 0.48% | 65 |
|
|
2021
Q2 | $8.91M | Buy |
79,126
+1,012
| +1% | +$114K | 0.51% | 60 |
|
|
2021
Q1 | $8.45M | Sell |
78,114
-102
| -0.1% | -$10.9K | 0.58% | 52 |
|
|
2020
Q4 | $8.38M | Buy |
78,216
+1,496
| +2% | +$144K | 0.6% | 49 |
|
|
2020
Q3 | $6.72M | Sell |
76,720
-295
| -0.4% | -$27.8K | 0.54% | 57 |
|
|
2020
Q2 | $7.56M | Buy |
77,015
+5,839
| +8% | +$514K | 0.63% | 44 |
|
|
2020
Q1 | $5.42M | Sell |
71,176
-1,087
| -2% | -$92.6K | 0.52% | 60 |
|
|
2019
Q4 | $6.4M | Buy |
72,263
+471
| +0.7% | +$39.1K | 0.49% | 68 |
|
|
2019
Q3 | $5.44M | Sell |
71,792
-262
| -0.4% | -$18K | 0.45% | 72 |
|
|
2019
Q2 | $5.24M | Sell |
72,054
-946
| -1% | -$74.4K | 0.43% | 74 |
|
|
2019
Q1 | $5.88M | Buy |
73,000
+2,328
| +3% | +$190K | 0.57% | 57 |
|
|
2018
Q4 | $6.66M | Buy |
70,672
+297
| +0.4% | +$26.1K | 0.69% | 48 |
|
|
2018
Q3 | $6.66M | Sell |
70,375
-894
| -1% | -$84.8K | 0.58% | 57 |
|
|
2018
Q2 | $6.6M | Sell |
71,269
-561
| -0.8% | -$54.8K | 0.61% | 51 |
|
|
2018
Q1 | $6.8M | Sell |
71,830
-3,827
| -5% | -$420K | 0.64% | 45 |
|
|
2017
Q4 | $7.32M | Sell |
75,657
-239
| -0.3% | -$22.5K | 0.66% | 45 |
|
|
2017
Q3 | $6.74M | Sell |
75,896
-521
| -0.7% | -$39.7K | 0.68% | 46 |
|
|
2017
Q2 | $5.54M | Sell |
76,417
-169
| -0.2% | -$11.4K | 0.58% | 57 |
|
|
2017
Q1 | $4.99M | Buy |
76,586
+433
| +0.6% | +$27.2K | 0.53% | 66 |
|
|
2016
Q4 | $4.77M | Buy |
76,153
+635
| +0.8% | +$38.8K | 0.53% | 64 |
|
|
2016
Q3 | $4.76M | Buy |
75,518
+18
| +0% | +$1.17K | 0.56% | 64 |
|
|
2016
Q2 | $4.67M | Buy |
75,500
+3,604
| +5% | +$220K | 0.56% | 60 |
|
|
2016
Q1 | $4.11M | Buy |
71,896
+2,173
| +3% | +$121K | 0.51% | 67 |
|
|
2015
Q4 | $4.13M | Sell |
69,723
-1,846
| -3% | -$106K | 0.52% | 64 |
|
|
2015
Q3 | $3.89M | Buy |
71,569
+601
| +0.8% | +$39.1K | 0.53% | 66 |
|
|
2015
Q2 | $4.77M | Buy |
70,968
+796
| +1% | +$52K | 0.6% | 58 |
|
|
2015
Q1 | $4.11M | Sell |
70,172
-1,455
| -2% | -$87.9K | 0.51% | 68 |
|
|
2014
Q4 | $4.69M | Sell |
71,627
-830
| -1% | -$52.3K | 0.58% | 60 |
|
|
2014
Q3 | $4.18M | Sell |
72,457
-6,749
| -9% | -$375K | 0.55% | 65 |
|
|
2014
Q2 | $4.47M | Sell |
79,206
-979
| -1% | -$51.4K | 0.58% | 60 |
|
|
2014
Q1 | $4.12M | Buy |
80,185
+9,611
| +14% | +$486K | 0.54% | 65 |
|
|
2013
Q4 | $3.73M | Sell |
70,574
-260
| -0.4% | -$12.8K | 0.52% | 67 |
|
|
2013
Q3 | $3.17M | Sell |
70,834
-859
| -1% | -$38.1K | 0.5% | 73 |
|
|
2013
Q2 | $2.96M | Buy |
+71,693
| New | +$3.14M | 0.49% | 72 |
|
Other funds holding ABBV
Dowling & Yahnke's ABBV Position: Q3 2022 in Review
Dowling & Yahnke reduced its AbbVie (ABBV) stake by 0.69% in Q3 2022, selling an estimated $78.2K and leaving 78,132 shares worth $10.5M. The position accounts for 0.49% of the portfolio, ranked #43.
Dowling & Yahnke first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $12.8M in Q1 2022. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Dowling & Yahnke held 78,132 shares of AbbVie worth $10.5M as of Q3 2022.
- Dowling & Yahnke sold 545 AbbVie shares in Q3 2022, an estimated $78.2K.
- AbbVie made up 0.49% of Dowling & Yahnke's portfolio in Q3 2022, its #43 holding.
- Dowling & Yahnke first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's AbbVie position peaked at $12.8M in Q1 2022.
- 2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.